ID   PAK4_MOUSE              Reviewed;         593 AA.
AC   Q8BTW9; Q6ZPX0; Q80Z97; Q9CS71;
DT   10-MAY-2004, integrated into UniProtKB/Swiss-Prot.
DT   01-MAR-2003, sequence version 1.
DT   07-APR-2021, entry version 154.
DE   RecName: Full=Serine/threonine-protein kinase PAK 4;
DE            EC=2.7.11.1;
DE   AltName: Full=p21-activated kinase 4;
DE            Short=PAK-4;
GN   Name=Pak4; Synonyms=Kiaa1142;
OS   Mus musculus (Mouse).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Mus; Mus.
OX   NCBI_TaxID=10090;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA], INTERACTION WITH FGFR2 AND GRB2, AND
RP   PHOSPHORYLATION AT TYROSINE RESIDUES.
RC   STRAIN=BALB/cJ;
RX   PubMed=12529371; DOI=10.1074/jbc.m205875200;
RA   Lu Y., Pan Z.-Z., Devaux Y., Ray P.;
RT   "p21-activated protein kinase 4 (PAK4) interacts with the keratinocyte
RT   growth factor receptor and participates in keratinocyte growth factor-
RT   mediated inhibition of oxidant-induced cell death.";
RL   J. Biol. Chem. 278:10374-10380(2003).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   TISSUE=Embryonic tail;
RX   PubMed=14621295; DOI=10.1093/dnares/10.4.167;
RA   Okazaki N., Kikuno R., Ohara R., Inamoto S., Koseki H., Hiraoka S.,
RA   Saga Y., Nagase T., Ohara O., Koga H.;
RT   "Prediction of the coding sequences of mouse homologues of KIAA gene: III.
RT   The complete nucleotide sequences of 500 mouse KIAA-homologous cDNAs
RT   identified by screening of terminal sequences of cDNA clones randomly
RT   sampled from size-fractionated libraries.";
RL   DNA Res. 10:167-180(2003).
RN   [3]
RP   SEQUENCE REVISION.
RA   Okazaki N., Kikuno R., Nagase T., Ohara O., Koga H.;
RL   Submitted (FEB-2005) to the EMBL/GenBank/DDBJ databases.
RN   [4]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=NOD; TISSUE=Embryo, and Thymus;
RX   PubMed=16141072; DOI=10.1126/science.1112014;
RA   Carninci P., Kasukawa T., Katayama S., Gough J., Frith M.C., Maeda N.,
RA   Oyama R., Ravasi T., Lenhard B., Wells C., Kodzius R., Shimokawa K.,
RA   Bajic V.B., Brenner S.E., Batalov S., Forrest A.R., Zavolan M., Davis M.J.,
RA   Wilming L.G., Aidinis V., Allen J.E., Ambesi-Impiombato A., Apweiler R.,
RA   Aturaliya R.N., Bailey T.L., Bansal M., Baxter L., Beisel K.W., Bersano T.,
RA   Bono H., Chalk A.M., Chiu K.P., Choudhary V., Christoffels A.,
RA   Clutterbuck D.R., Crowe M.L., Dalla E., Dalrymple B.P., de Bono B.,
RA   Della Gatta G., di Bernardo D., Down T., Engstrom P., Fagiolini M.,
RA   Faulkner G., Fletcher C.F., Fukushima T., Furuno M., Futaki S.,
RA   Gariboldi M., Georgii-Hemming P., Gingeras T.R., Gojobori T., Green R.E.,
RA   Gustincich S., Harbers M., Hayashi Y., Hensch T.K., Hirokawa N., Hill D.,
RA   Huminiecki L., Iacono M., Ikeo K., Iwama A., Ishikawa T., Jakt M.,
RA   Kanapin A., Katoh M., Kawasawa Y., Kelso J., Kitamura H., Kitano H.,
RA   Kollias G., Krishnan S.P., Kruger A., Kummerfeld S.K., Kurochkin I.V.,
RA   Lareau L.F., Lazarevic D., Lipovich L., Liu J., Liuni S., McWilliam S.,
RA   Madan Babu M., Madera M., Marchionni L., Matsuda H., Matsuzawa S., Miki H.,
RA   Mignone F., Miyake S., Morris K., Mottagui-Tabar S., Mulder N., Nakano N.,
RA   Nakauchi H., Ng P., Nilsson R., Nishiguchi S., Nishikawa S., Nori F.,
RA   Ohara O., Okazaki Y., Orlando V., Pang K.C., Pavan W.J., Pavesi G.,
RA   Pesole G., Petrovsky N., Piazza S., Reed J., Reid J.F., Ring B.Z.,
RA   Ringwald M., Rost B., Ruan Y., Salzberg S.L., Sandelin A., Schneider C.,
RA   Schoenbach C., Sekiguchi K., Semple C.A., Seno S., Sessa L., Sheng Y.,
RA   Shibata Y., Shimada H., Shimada K., Silva D., Sinclair B., Sperling S.,
RA   Stupka E., Sugiura K., Sultana R., Takenaka Y., Taki K., Tammoja K.,
RA   Tan S.L., Tang S., Taylor M.S., Tegner J., Teichmann S.A., Ueda H.R.,
RA   van Nimwegen E., Verardo R., Wei C.L., Yagi K., Yamanishi H.,
RA   Zabarovsky E., Zhu S., Zimmer A., Hide W., Bult C., Grimmond S.M.,
RA   Teasdale R.D., Liu E.T., Brusic V., Quackenbush J., Wahlestedt C.,
RA   Mattick J.S., Hume D.A., Kai C., Sasaki D., Tomaru Y., Fukuda S.,
RA   Kanamori-Katayama M., Suzuki M., Aoki J., Arakawa T., Iida J., Imamura K.,
RA   Itoh M., Kato T., Kawaji H., Kawagashira N., Kawashima T., Kojima M.,
RA   Kondo S., Konno H., Nakano K., Ninomiya N., Nishio T., Okada M., Plessy C.,
RA   Shibata K., Shiraki T., Suzuki S., Tagami M., Waki K., Watahiki A.,
RA   Okamura-Oho Y., Suzuki H., Kawai J., Hayashizaki Y.;
RT   "The transcriptional landscape of the mammalian genome.";
RL   Science 309:1559-1563(2005).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA].
RC   STRAIN=FVB/N; TISSUE=Colon;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [6]
RP   FUNCTION IN PHOSPHORYLATION OF LIMK1.
RX   PubMed=11413130; DOI=10.1074/jbc.m100871200;
RA   Dan C., Kelly A., Bernard O., Minden A.;
RT   "Cytoskeletal changes regulated by the PAK4 serine/threonine kinase are
RT   mediated by LIM kinase 1 and cofilin.";
RL   J. Biol. Chem. 276:32115-32121(2001).
RN   [7]
RP   DISRUPTION PHENOTYPE.
RX   PubMed=14517283; DOI=10.1128/mcb.23.20.7122-7133.2003;
RA   Qu J., Li X., Novitch B.G., Zheng Y., Kohn M., Xie J.M., Kozinn S.,
RA   Bronson R., Beg A.A., Minden A.;
RT   "PAK4 kinase is essential for embryonic viability and for proper neuronal
RT   development.";
RL   Mol. Cell. Biol. 23:7122-7133(2003).
RN   [8]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-476, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Embryonic brain;
RX   PubMed=15345747; DOI=10.1074/mcp.m400085-mcp200;
RA   Ballif B.A., Villen J., Beausoleil S.A., Schwartz D., Gygi S.P.;
RT   "Phosphoproteomic analysis of the developing mouse brain.";
RL   Mol. Cell. Proteomics 3:1093-1101(2004).
RN   [9]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-476, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Liver;
RX   PubMed=17242355; DOI=10.1073/pnas.0609836104;
RA   Villen J., Beausoleil S.A., Gerber S.A., Gygi S.P.;
RT   "Large-scale phosphorylation analysis of mouse liver.";
RL   Proc. Natl. Acad. Sci. U.S.A. 104:1488-1493(2007).
RN   [10]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-181, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19144319; DOI=10.1016/j.immuni.2008.11.006;
RA   Trost M., English L., Lemieux S., Courcelles M., Desjardins M.,
RA   Thibault P.;
RT   "The phagosomal proteome in interferon-gamma-activated macrophages.";
RL   Immunity 30:143-154(2009).
RN   [11]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT SER-476, AND IDENTIFICATION BY
RP   MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RC   TISSUE=Brain, Heart, Kidney, Liver, Lung, Pancreas, Spleen, and Testis;
RX   PubMed=21183079; DOI=10.1016/j.cell.2010.12.001;
RA   Huttlin E.L., Jedrychowski M.P., Elias J.E., Goswami T., Rad R.,
RA   Beausoleil S.A., Villen J., Haas W., Sowa M.E., Gygi S.P.;
RT   "A tissue-specific atlas of mouse protein phosphorylation and expression.";
RL   Cell 143:1174-1189(2010).
RN   [12]
RP   FUNCTION.
RX   PubMed=21381077; DOI=10.1002/jcb.23092;
RA   Nekrasova T., Minden A.;
RT   "PAK4 is required for regulation of the cell-cycle regulatory protein p21,
RT   and for control of cell-cycle progression.";
RL   J. Cell. Biochem. 112:1795-1806(2011).
RN   [13]
RP   DISRUPTION PHENOTYPE.
RX   PubMed=21382368; DOI=10.1016/j.ydbio.2011.02.026;
RA   Tian Y., Lei L., Minden A.;
RT   "A key role for Pak4 in proliferation and differentiation of neural
RT   progenitor cells.";
RL   Dev. Biol. 353:206-216(2011).
CC   -!- FUNCTION: Serine/threonine protein kinase that plays a role in a
CC       variety of different signaling pathways including cytoskeleton
CC       regulation, cell migration, growth, proliferation or cell survival.
CC       Activation by various effectors including growth factor receptors or
CC       active CDC42 and RAC1 results in a conformational change and a
CC       subsequent autophosphorylation on several serine and/or threonine
CC       residues. Phosphorylates and inactivates the protein phosphatase SSH1,
CC       leading to increased inhibitory phosphorylation of the actin
CC       binding/depolymerizing factor cofilin. Decreased cofilin activity may
CC       lead to stabilization of actin filaments. Phosphorylates LIMK1, a
CC       kinase that also inhibits the activity of cofilin. Phosphorylates
CC       integrin beta5/ITGB5 and thus regulates cell motility. Phosphorylates
CC       ARHGEF2 and activates the downstream target RHOA that plays a role in
CC       the regulation of assembly of focal adhesions and actin stress fibers.
CC       Stimulates cell survival by phosphorylating the BCL2 antagonist of cell
CC       death BAD. Alternatively, inhibits apoptosis by preventing caspase-8
CC       binding to death domain receptors in a kinase independent manner. Plays
CC       a role in cell-cycle progression by controlling levels of the cell-
CC       cycle regulatory protein CDKN1A and by phosphorylating RAN.
CC       {ECO:0000269|PubMed:11413130, ECO:0000269|PubMed:21381077}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.1;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.1;
CC   -!- ACTIVITY REGULATION: Inhibited by INKA1; which inhibits the
CC       serine/threonine-protein kinase activity by binding PAK4 in a
CC       substrate-like manner. {ECO:0000250|UniProtKB:O96013}.
CC   -!- SUBUNIT: Interacts tightly with GTP-bound but not GDP-bound CDC42/p21
CC       and weakly with RAC1 (By similarity). Interacts with FGFR2 and GRB2
CC       (PubMed:12529371). Interacts with INKA1. Interacts with SH3RF2 (By
CC       similarity). {ECO:0000250|UniProtKB:O96013,
CC       ECO:0000269|PubMed:12529371}.
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250|UniProtKB:O96013}.
CC       Note=Seems to shuttle between cytoplasmic compartments depending on the
CC       activating effector. For example, can be found on the cell periphery
CC       after activation of growth-factor or integrin-mediated signaling
CC       pathways. {ECO:0000250|UniProtKB:O96013}.
CC   -!- PTM: Autophosphorylated on serine residues when activated by CDC42/p21
CC       (By similarity). Phosphorylated on tyrosine residues upon stimulation
CC       of FGFR2 (PubMed:12529371). {ECO:0000250|UniProtKB:O96013,
CC       ECO:0000269|PubMed:12529371}.
CC   -!- PTM: Polyubiquitinated, leading to its proteasomal degradation.
CC       {ECO:0000250|UniProtKB:O96013}.
CC   -!- DISRUPTION PHENOTYPE: Mice die at embryonic day 11.5 probably due to a
CC       defect in the fetal heart. They show strong defects in neuronal
CC       development and axonal outgrowth. Spinal cord motor neurons and
CC       interneurons failed to differentiate and migrate to their proper
CC       position. Nervous system-specific conditional PAK4 deletion mice
CC       display growth retardation and die prematurely.
CC       {ECO:0000269|PubMed:14517283, ECO:0000269|PubMed:21382368}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. STE Ser/Thr
CC       protein kinase family. STE20 subfamily. {ECO:0000305}.
CC   -!- SEQUENCE CAUTION:
CC       Sequence=BAC98108.2; Type=Erroneous initiation; Evidence={ECO:0000305};
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AY217016; AAO61496.1; -; mRNA.
DR   EMBL; AK129298; BAC98108.2; ALT_INIT; mRNA.
DR   EMBL; AK017713; BAB30889.1; -; mRNA.
DR   EMBL; AK088512; BAC40396.1; -; mRNA.
DR   EMBL; BC048238; AAH48238.1; -; mRNA.
DR   CCDS; CCDS21049.1; -.
DR   RefSeq; NP_081746.1; NM_027470.3.
DR   RefSeq; XP_017167785.1; XM_017312296.1.
DR   RefSeq; XP_017167786.1; XM_017312297.1.
DR   BioGRID; 214149; 4.
DR   IntAct; Q8BTW9; 1.
DR   MINT; Q8BTW9; -.
DR   iPTMnet; Q8BTW9; -.
DR   PhosphoSitePlus; Q8BTW9; -.
DR   EPD; Q8BTW9; -.
DR   jPOST; Q8BTW9; -.
DR   MaxQB; Q8BTW9; -.
DR   PaxDb; Q8BTW9; -.
DR   PeptideAtlas; Q8BTW9; -.
DR   PRIDE; Q8BTW9; -.
DR   ProteomicsDB; 294376; -.
DR   Antibodypedia; 16732; 612 antibodies.
DR   Ensembl; ENSMUST00000032823; ENSMUSP00000032823; ENSMUSG00000030602.
DR   Ensembl; ENSMUST00000108283; ENSMUSP00000103918; ENSMUSG00000030602.
DR   GeneID; 70584; -.
DR   KEGG; mmu:70584; -.
DR   UCSC; uc009fzh.1; mouse.
DR   CTD; 10298; -.
DR   MGI; MGI:1917834; Pak4.
DR   GeneTree; ENSGT00940000159792; -.
DR   HOGENOM; CLU_000288_26_6_1; -.
DR   InParanoid; Q8BTW9; -.
DR   OMA; HNMAPNG; -.
DR   OrthoDB; 757766at2759; -.
DR   PhylomeDB; Q8BTW9; -.
DR   TreeFam; TF105352; -.
DR   BioGRID-ORCS; 70584; 0 hits in 52 CRISPR screens.
DR   ChiTaRS; Pak4; mouse.
DR   PRO; PR:Q8BTW9; -.
DR   Proteomes; UP000000589; Chromosome 7.
DR   RNAct; Q8BTW9; protein.
DR   Bgee; ENSMUSG00000030602; Expressed in zygote and 271 other tissues.
DR   Genevisible; Q8BTW9; MM.
DR   GO; GO:0005737; C:cytoplasm; IBA:GO_Central.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004672; F:protein kinase activity; IDA:MGI.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; ISS:UniProtKB.
DR   GO; GO:0106311; F:protein threonine kinase activity; IEA:UniProtKB-EC.
DR   GO; GO:0032147; P:activation of protein kinase activity; IBA:GO_Central.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0007049; P:cell cycle; IEA:UniProtKB-KW.
DR   GO; GO:0071407; P:cellular response to organic cyclic compound; IDA:MGI.
DR   GO; GO:0060996; P:dendritic spine development; IGI:MGI.
DR   GO; GO:2000352; P:negative regulation of endothelial cell apoptotic process; ISO:MGI.
DR   GO; GO:0045766; P:positive regulation of angiogenesis; ISO:MGI.
DR   GO; GO:0031098; P:stress-activated protein kinase signaling cascade; IBA:GO_Central.
DR   CDD; cd01093; CRIB_PAK_like; 1.
DR   Gene3D; 3.90.810.10; -; 1.
DR   InterPro; IPR000095; CRIB_dom.
DR   InterPro; IPR036936; CRIB_dom_sf.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR033923; PAK_BD.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   Pfam; PF00786; PBD; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   SMART; SM00285; PBD; 1.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS50108; CRIB; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
PE   1: Evidence at protein level;
KW   Apoptosis; ATP-binding; Cell cycle; Cytoplasm; Kinase; Methylation;
KW   Nucleotide-binding; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   CHAIN           1..593
FT                   /note="Serine/threonine-protein kinase PAK 4"
FT                   /id="PRO_0000086475"
FT   DOMAIN          11..24
FT                   /note="CRIB"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00057"
FT   DOMAIN          323..574
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   NP_BIND         329..337
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   REGION          25..322
FT                   /note="Linker"
FT   COMPBIAS        4..7
FT                   /note="Poly-Lys"
FT   COMPBIAS        105..108
FT                   /note="Poly-Pro"
FT   COMPBIAS        216..298
FT                   /note="Pro-rich"
FT   COMPBIAS        242..246
FT                   /note="Poly-Ser"
FT   ACT_SITE        442
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   BINDING         352
FT                   /note="ATP"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOD_RES         41
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O96013"
FT   MOD_RES         78
FT                   /note="N6-methyllysine"
FT                   /evidence="ECO:0000250|UniProtKB:O96013"
FT   MOD_RES         104
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O96013"
FT   MOD_RES         148
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O96013"
FT   MOD_RES         181
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0007744|PubMed:19144319"
FT   MOD_RES         187
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:O96013"
FT   MOD_RES         195
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O96013"
FT   MOD_RES         207
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0000250|UniProtKB:O96013"
FT   MOD_RES         257
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O96013"
FT   MOD_RES         266
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O96013"
FT   MOD_RES         293
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:O96013"
FT   MOD_RES         476
FT                   /note="Phosphoserine; by autocatalysis"
FT                   /evidence="ECO:0007744|PubMed:15345747,
FT                   ECO:0007744|PubMed:17242355, ECO:0007744|PubMed:21183079"
FT   CONFLICT        5
FT                   /note="K -> R (in Ref. 1; AAO61496)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        248
FT                   /note="P -> L (in Ref. 1; AAO61496)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        564
FT                   /note="T -> P (in Ref. 4; BAB30889)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   593 AA;  64623 MW;  4AFA91DD73D4C6D5 CRC64;
     MFGKKKKRVE ISAPSNFEHR VHTGFDQHEQ KFTGLPRQWQ SLIEESARRP KPLIDPACIT
     SIQPGAPKTI VRGSKGAKDG ALTLLLDEFE NMSVTRSNSL RRESPPPPAR AHQENGMLEE
     RAAPARMAPD KAGSRARATG HSEAGSGSGD RRRVGPEKRP KSSRDGPGGP QEASRDKRPL
     SGPDVSTPQP GSLTSGTKLA AGRPFNTYPR ADTDHPPRGA QGEPHTMAPN GPSATGLAAP
     QSSSSSRPPT RARGAPSPGV LGPHASEPQL APPARALAAP AVPPAPGPPG PRSPQREPQR
     VSHEQFRAAL QLVVDPGDPR SYLDNFIKIG EGSTGIVCIA TVRSSGKLVA VKKMDLRKQQ
     RRELLFNEVV IMRDYRHENV VEMYNSYLVG DELWVVMEFL EGGALTDIVT HTRMNEEQIA
     AVCLAVLQAL AVLHAQGVIH RDIKSDSILL THDGRVKLSD FGFCAQVSKE VPRRKSLVGT
     PYWMAPELIS RLPYGPEVDI WSLGVMVIEM VDGEPPYFNE PPLKAMKMIR DNLPPRLKNL
     HKASPSLKGF LDRLLVRDPA QRATAAELLK HPFLTKAGPP ASIVPLMRQH RTR
//
